Skip to Main Content

Paper Details

A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease.
J Crohns Colitis
2
2023
Author NameAffiliation
Bruce E SandsIcahn School of Medicine at Mount Sinai
  • 1 - 1

Datasets

Release 1.2